🔗 Share this article

Ministers and senior MPs have expressed alarm that the United Kingdom's negotiated accords with Donald Trump are "lacking a solid foundation." This comes after revelations that a recently announced deal on pharmaceutical tariffs, which promises zero tariffs in exchange for the NHS increasing its costs, lacks any detailed agreement beyond vague headline terms published in government press releases.

An Agreement in Principle Only

The arrangement concerning medicines, described as a "generational" achievement, exists as an "statement of intent" without detailed provisions. Observers point out that the official announcements from the UK and US governments describe the deal in sharply different terms. The British version focuses on securing "duty-free access" as a singular success, while the American announcement dwells on the agreement for the NHS to pay 25% more for new medications.

"There is a serious risk that the UK government has made commitments to increase medicine costs in return for nothing more than a verbal promise from President Trump," commented David Henig, a trade expert. "We know he has form for not keeping promises."

Wider Concerns Amidst a Suspended Agreement

Concerns have been amplified by Washington's action to suspend the high-value digital accord, which was previously called "a transformative pact" in the bilateral relationship. The US claimed a insufficient movement from the UK on reducing other tariffs as the reason for the pause.

Additionally, concessions secured for British farmers as part of an May trade agreement have not been formally signed off by the US, despite a imminent January deadline. "Our understanding is that the US has not finalized the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

In confidential discussions, ministers have expressed concerns that the government's deals with Washington are flimsy and unreliable. One minister reportedly said the series of agreements as "resting on shaky ground," while another framed the situation as the "current reality" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, chair of the health select committee, remarked: "The only thing more surprising than the US approach is the UK government's credulous faith that his administration is a trustworthy negotiator. The NHS is of vital importance."

A Mixed Picture of Success and Setback

Officials have downplayed the possibility of the US backing out of the pharmaceuticals deal. One source suggested the US pharmaceutical industry itself had been pushing for the agreement, desiring stability on imports and pricing, making it of tangible value than the paused tech deal.

Officials admit that unpredictability is part and parcel of dealing with the Trump administration. However, they contend that the UK has achieved real benefits for businesses, such as reduced duties on automobiles compared to other nations. "The fact we have 25% steel tariffs, which is lower than the rate for the rest of the world, is a solid gain," one official said.

Nevertheless, delays have surfaced in enacting the initial US-UK accord. Promised access for British beef have failed to be approved, and the commitment to "remove tariffs on British steel and aluminium" has not been fulfilled, with tariffs remaining at 25%.

Moving forward, the two sides have agreed to resume talks on the paused tech prosperity deal in January, following what were described as "very positive" meetings between UK and US officials in Washington.